BRYNOVIN
Sitagliptin Hydrochloride Oral
- Strength
- 25 mg/mL
- Form
- Solution
- Class
- Dipeptidyl Peptidase 4 Inhibitor
Azurity Pharmaceuticals, Inc.
Listed by Sandoz Inc
| Dosage form | Tablet, Film Coated |
|---|---|
| Route | Oral |
| Drug class | Dipeptidyl Peptidase 4 Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 0781-5768 |
| FDA application | ANDA202387 |
| RxNorm concept | 2709603 |
| Package sizes listed | 2 |
| Marketed since | January 2026 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Sitagliptin Hydrochloride Oral
Azurity Pharmaceuticals, Inc.
sitagliptin
Merck Sharp & Dohme LLC
sitagliptin
A-S Medication Solutions
sitagliptin
Cardinal Health 107, LLC
sitagliptin
A-S Medication Solutions
sitagliptin
Merck Sharp & Dohme LLC
sitagliptin
A-S Medication Solutions
sitagliptin
A-S Medication Solutions
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.